Opinion|Videos|January 20, 2025
Final Thoughts on Identifying and Managing Patients with T1D
Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.
Advertisement
Episodes in this series
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
2
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
3
Why Real-World Evidence Matters for Nonhormonal Menopause VMS Therapy
4
Real-World Nonhormonal Therapy Effects on VMS Bother, Work, and Mood
5